Product description

The monoclonal antibody JC4 is specific for Cytotoxic necrotizing factor type 1 and the highly related Cytotoxic necrotizing factor type 2 (CNF1 and CNF2) of uropathogenic Escherichia coli. CNF1 and 2 belong to a family of bacterial toxins that target the small GTP-binding Rho proteins that regulate the actin cytoskeleton. Members of this toxin family typically inactivate Rho; however, CNF1 and the CNF2 activate Rho by deamidation. CNF1 is more frequently associated with E.coli strains that cause extraintestitinal infections in humans, particularly those of the urinary tract (such as cystitis, pyelonephritis and prostatitis). In CNF1-producing uropathogenic E. coli strains, CNF1 is chromosomally encoded and typically resides on a pathogenicity island that also contains hemolysin and P fimbria- related genes. Both CNF1 and the highly related, plasmid-encoded CNF2 are monomeric, cytoplasmic toxins of approximately 115 kDa. CNF1 can be structurally organized into three functional domains the N-terminal binding domain, central and the C-terminal domain. The latter exhibits the catalytic activity of the toxin. Monoclonal antibody JC4 recognizes an epitope between amino acids 169 to 191 of the N-terminal binding domain. JC4 neutralizes only CNF1.

Specifications
Applications
WB, ELISA, FUNC
Isotype
Mouse IgG2a
Supplier
Hycult Biotech
Shipping & storage
Shipping condition
Room Temperature
Storage temperature
2-8°C

Order your product by email

Productname

CNF1/CNF2, mAb JC4

HM6006-100UG

By filling out this form, you are placing an order by e-mail. You will receive an order confirmation within one working day. The order cannot be modified after receipt of the order confirmation.


Request a sample

Productname

CNF1/CNF2, mAb JC4

HM6006-100UG

By filling out this form, you request a sample. You will receive an order confirmation within one working day. The order cannot be modified after receipt of the order confirmation.


Organization information

*Required fields


Are you looking for specific products, alternatives or documentation?